Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli ™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical opera...
TAMPA, FLORIDA / ACCESS Newswire / October 13, 2025 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the re-appointment of Prashant Patel, RPh as President, Interim-CEO and Member of the Board of Directors. Mr. Patel had resigned from t...
Arbli ™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life
Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announ...
COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the shipment of launc...
Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its boa...
Commack, NY, July 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has ...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.